CGTLimited DatastaleImmune Design, a subsidiary of …Phase 1
Dendritic Cell-targeting Lentiviral Vector ID-LV305 (Dendritic Cell-targeting Lentiviral Vector ID-LV305)
HLA-A*0201 Positive Cells Present; NY-ESO-1 Positive Tumor Cells Present · HLA-A*0201 Positive Cells Present
#HLA-A0201PositiveCellsPresent#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Active